Popular Trials
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor
JNJ-64619178 for Cancer
Recruiting1 awardPhase 1
Sarasota, Florida
This trial is testing a new cancer drug to see what doses are tolerated by patients with different types of cancer, including lymphoma and solid tumors. The goal is to also find out what doses of the drug might be effective in treating these cancers.
Radioactive Agent
Iobenguane (131-I) + Vorinostat for Neuroblastoma
Recruiting1 awardPhase 2
San Francisco, California
This trial tests a combination of a radioactive drug and a cancer-fighting pill in patients with a specific type of neuroblastoma that hasn't responded well to other treatments. The radioactive drug kills cancer cells, and the pill makes them more vulnerable to the drug.
JAK Inhibitor
MMB for Myelofibrosis
Recruiting1 awardPhase 2
Orange, California
This trial aims to provide ongoing access to momelotinib for patients with certain types of myelofibrosis who are already taking the drug and have not seen their disease get worse. The study will also look at how long these patients live without developing leukemia. Momelotinib has been studied for myelofibrosis and other related conditions.
Popular Filters
Trials for Tumors Patients
Behavioral Intervention
Exercise Program for Cancer
Recruiting1 award
Calgary, Alberta
This trial is testing the ACE Program, a structured exercise plan for adult cancer survivors. The program aims to improve their physical well-being and quality of life through consistent, personalized exercise. It may also help prevent new cancers from developing.
Monoclonal Antibodies
TSR-022 for Cancer
Recruiting1 awardPhase 1
Phoenix, Arizona
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Trials for Adenocarcinoma Patients
OC-001 for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Edmonton, Alberta
This trial is testing a new treatment called OC-001, both by itself and with other drugs that help the immune system fight cancer. It aims to help patients with various types of cancer by making their immune system better at attacking cancer cells.
Monoclonal Antibodies
STAR0602 for Advanced Cancers
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a new drug called STAR0602 to see if it is safe and effective for treating advanced cancers with specific markers. The drug is given through an IV and aims to find and destroy cancer cells by recognizing these markers. The study will first determine the best dose and then see how well the drug works in patients.
Behavioral Intervention
Group Exercise Program for Prostate Cancer Survivors and Caregivers
Recruiting1 award10 criteria
Tucson, Arizona
This trial explores how an adapted group exercise program can improve physical/mental health of prostate cancer survivors & their informal caregivers. Participants will take part in supervised classes via videoconferencing for 3-months, with 3-months follow-up.
Cancer Vaccine
EO-3021 for Gastrointestinal Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing a new treatment for adult patients with solid tumors that have a specific marker called CLDN18.2. The treatment aims to find and destroy cancer cells with this marker. This approach helps target the cancer more precisely without affecting normal cells. CLDN18.2 has been identified as a promising target for cancer therapy, particularly in gastric cancer.
Trials for Metastatic Patients
Monoclonal Antibodies
TSR-022 for Cancer
Recruiting1 awardPhase 1
Phoenix, Arizona
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Monoclonal Antibodies
MK-4830 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
San Francisco, California
This trial is testing a new drug called MK-4830 alone and with other cancer treatments to see if it is safe and effective. It focuses on cancer patients, including those in China. The treatments work by helping the immune system fight cancer and killing cancer cells.
MDM2 Inhibitor
BI 907828 for Advanced Cancer
Recruiting1 awardPhase 1
New Haven, Connecticut
This trial is testing a new cancer drug, BI 907828, to see if it's effective and safe. Participants will take BI 907828 either once every three weeks or twice every four weeks, depending on how well they tolerate the drug. The goal is to see if BI 907828 causes tumors to shrink.
Phase 3 Trials
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Monoclonal Antibodies
Octreotide + Interferon/Bevacizumab for Neuroendocrine Tumors
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is comparing two treatments for neuroendocrine tumors - octreotide acetate with either recombinant interferon alfa-2b or bevacizumab. The goal is to see if octreotide acetate with recombinant interferon alfa-2b is more effective than with bevacizumab.
Trials With No Placebo
Behavioral Intervention
Exercise Program for Cancer
Recruiting1 award
Calgary, Alberta
This trial is testing the ACE Program, a structured exercise plan for adult cancer survivors. The program aims to improve their physical well-being and quality of life through consistent, personalized exercise. It may also help prevent new cancers from developing.
Monoclonal Antibodies
TSR-022 for Cancer
Recruiting1 awardPhase 1
Phoenix, Arizona
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
Monoclonal Antibodies
Dostarlimab for Advanced Cancer
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.